A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Am J Hematol. 2023 Dec;98(12):E387-E390. doi: 10.1002/ajh.27110. Epub 2023 Oct 9.

Authors

Adam S Kittai¹, Alan Skarbnik², Miguel Miranda³, Alan S M Yong⁴, Jack Roos⁴, Robert Hettle³, Sarah Palazuelos-Munoz⁴, Vikram Shetty⁴, Paolo Ghia⁵

Affiliations

¹ Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
² Novant Health Cancer Institute, Lymphoma and Chronic Lymphocytic Leukemia Program, Charlotte, North Carolina, USA.
³ AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK.
⁴ AstraZeneca, Gaithersburg, Maryland, USA.
⁵ Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.

PMID: 37811799
DOI: 10.1002/ajh.27110

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Protein Kinase Inhibitors / adverse effects
Pyrazines / adverse effects

Substances

acalabrutinib
zanubrutinib
Antineoplastic Agents
Pyrazines
Protein Kinase Inhibitors